ABBVIE INC. (ABBV) stock
ABBVIE INC. (ABBV) trades on NYSE and is classified in the Technology sector. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio. This page tracks ABBV using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$285.99
Volume
4,323,182
52-week range
$190.75 – $292.67
Market cap
$505.38B
Source: Polygon (snapshot) · Verified Oct 29, 2026, 5:51 PM EDT
Performance
1D
+2.59%
1W
+1.96%
1M
+10.44%
1Y
+29.16%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Reported financials
Verified · 87 days agoRevenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Aug 2, 2026, 8:00 PM EDT
Valuation
P/E (trailing)
Reported Q2'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)
P/E (forward, est.)
Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Earnings
Verified · 87 days agoNext earnings date
Oct 29, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $16.99B · Diluted EPS 2.03
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | 3.65 | 3.68 | -0.7% |
| 2026-03-31 | 2.65 | 2.65 | +0.2% |
| 2025-12-31 | 2.71 | 2.71 | +0.2% |
| 2025-09-30 | 1.86 | 1.81 | +2.7% |
Ticker-Terminal analysis of ABBV
Earnings-power range
Bear $62.76 · Base $78.45 · Bull $94.14 — Significantly Overvalued versus the last verified price.
Bull case
Sustained growth and margin strength support roughly $94.14.
- Applies a 22× earnings multiple to trailing diluted EPS of 3.54, plus a 20% upside band.
- Latest reported revenue growth: 10.2% year over year.
- Trailing operating margin: 26.2%.
Base case
Current reported earnings power maps to roughly $78.45 (significantly overvalued versus the last verified price).
- Earnings-power estimate: trailing diluted EPS × a growth-adjusted 22× multiple.
- Implied difference versus the last verified price: -73.3%.
- Trailing operating cash flow: $19.51B.
Bear case
Multiple compression or slowing growth maps to roughly $62.76.
- Applies a 20% downside band to the earnings-power estimate.
- Latest reported EPS growth: 290.4% year over year.
- Downside from the last verified price in this scenario: -78.6%.
Calculated from verified reported financials and the last verified price (data verified Oct 29, 2026, 5:51 PM EDT). Analytical model output, not a price target or investment advice.
Analyst consensus
UnavailableRating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
39
Source: finnhub
Recent ABBV news
Verified · 12 hours ago- AbbVie (ABBV) reports earnings tomorrow: what to expect
Yahoo Finance · Oct 29, 2026
- Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
Zacks Investment Research · Oct 27, 2026
- AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple Myeloma
Yahoo Finance · Oct 28, 2026
- AbbVie: Still Strong Growth, But Patent Cliff Getting Closer
Seeking Alpha · Oct 28, 2026
- AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)
Seeking Alpha · Oct 27, 2026
- AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
Yahoo Finance · Oct 29, 2026
Data confidence: Partial confidence
Some data is delayed, stale or unavailable. Everything shown is still verified.
- Market data is delayed.
What is affected
- Market dataDelayed · 30 minutes ago· Polygon (snapshot)
Still fully reliable
Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis
Compare This Stock
ABBV in its sector
Run full AI research on ABBV
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
ABBV questions, answered
What does ABBVIE INC. do?
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Where is ABBV listed?
ABBVIE INC. trades under the ticker ABBV on NYSE.
What is the ABBV stock price today?
ABBV was last verified at $293.40 (2.59% on the day). After hours, last verified Oct 29, 2026, 5:51 PM EDT. Market data may be delayed and is shown with its own timestamp.
Is ABBVIE INC. revenue growing?
Based on the latest reported financials, ABBV revenue changed 10.2% year over year (filed Aug 2, 2026).
When does ABBVIE INC. report earnings next?
The next confirmed ABBV earnings date is Oct 29, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
What did ABBVIE INC. report in its latest quarter?
For Q2'26, ABBV reported revenue of $16.99B and diluted EPS of 2.03.
What is Ticker-Terminal's ABBV growth score?
Ticker-Terminal scores ABBV at 48/100 (F) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.
How can I run deeper AI research on ABBV?
Create a free Ticker-Terminal account to run a full AI research report on ABBV — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Learn how to read this
Free guide series
Get the “how to research a stock” checklist
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
- The 7-step “how to research a stock” checklist, sent immediately
- The next recommended guide in the series, two days later
- Occasional new guides only — no daily market noise, unsubscribe in one click
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from ABBV's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 29, 2026, 6:21 PM EDT.